0001104659-22-121285.txt : 20221122 0001104659-22-121285.hdr.sgml : 20221122 20221122170043 ACCESSION NUMBER: 0001104659-22-121285 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221121 FILED AS OF DATE: 20221122 DATE AS OF CHANGE: 20221122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Khattar Jack A. CENTRAL INDEX KEY: 0001539937 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 221411293 MAIL ADDRESS: STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC. STREET 2: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 4 1 tm2231147-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-11-21 0 0001356576 SUPERNUS PHARMACEUTICALS, INC. SUPN 0001539937 Khattar Jack A. C/O SUPERNUS PHARMACEUTICALS, INC. 9715 KEY WEST AVENUE ROCKVILLE MD 20850 1 1 0 0 President, CEO Common Stock 2022-11-21 4 M 0 848 9.56 A 781590 D Common Stock 2022-11-21 4 S 0 531 35.0136 D 781059 D Common Stock 1047700 I By the KBT Trust Common Stock 4000 I By son Employee Stock Option (Right to Buy) 9.56 2022-11-21 4 M 0 848 0 D 2024-01-23 Common Stock 848 147369 D Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.04, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. The options vested in four equal annual installments beginning on January 23, 2015. /s/ Timothy C. Dec, as attorney-in-fact 2022-11-22